QI
ALNY icon

QS Investors’s Alnylam Pharmaceuticals ALNY Stock Holding History

QS Investors’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		$361K Sell
2,124
-200
-9% -$29.3K ﹤0.01% 865
2021
Q1 		$329K Hold
2,324
– – ﹤0.01% 953
2020
Q4 		$302K Buy
2,324
+224
+11% +$29.9K ﹤0.01% 988
2020
Q3 		$306K Sell
2,100
-500
-19% -$71.1K ﹤0.01% 908
2020
Q2 		$386K Buy
2,600
+200
+8% +$27K 0.01% 975
2020
Q1 		$262K Hold
2,400
– – ﹤0.01% 999
2019
Q4 		$278K Hold
2,400
– – ﹤0.01% 1103
2019
Q3 		$194K Hold
2,400
– – ﹤0.01% 1210
2019
Q2 		$175K Hold
2,400
– – ﹤0.01% 1253
2019
Q1 		$225K Sell
2,400
-8
-0.3% -$669 ﹤0.01% 1178
2018
Q4 		$176K Hold
2,408
– – ﹤0.01% 1166
2018
Q3 		$211K Hold
2,408
– – ﹤0.01% 1190
2018
Q2 		$237K Hold
2,408
– – ﹤0.01% 1155
2018
Q1 		$287K Hold
2,408
– – ﹤0.01% 1074
2017
Q4 		$306K Hold
2,408
– – ﹤0.01% 1064
2017
Q3 		$283K Hold
2,408
– – ﹤0.01% 1103
2017
Q2 		$192K Buy
2,408
+900
+60% +$57.5K ﹤0.01% 1227
2017
Q1 		$77K Buy
1,508
+1,500
+18,750% +$69.3K ﹤0.01% 1434
2016
Q4 		$1K Hold
8
– – ﹤0.01% 1525
2016
Q3 		$1K Hold
8
– – ﹤0.01% 1511
2016
Q2 		$1K Hold
8
– – ﹤0.01% 1532
2016
Q1 		$1K Hold
8
– – ﹤0.01% 1531
2015
Q4 		$1K Buy
+8
New +$742 ﹤0.01% 1539
2015
Q3 		– Sell
-17,100
Closed -$2.05M – 1436
2015
Q2 		$2.05M Buy
+17,100
New +$2.04M 0.03% 612
2013
Q3 		– Sell
-136,100
Closed -$4.22M – 585
2013
Q2 		$4.22M Buy
+136,100
New +$3.62M 0.15% 188

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

QS Investors's ALNY Position: Q2 2021 in Review

QS Investors reduced its Alnylam Pharmaceuticals (ALNY) stake by 8.6% in Q2 2021, selling an estimated $29.3K and leaving 2,124 shares worth $361K. The position accounts for ﹤0.01% of the portfolio, ranked #865.

QS Investors first reported a position in ALNY in Q2 2013 and has held it in 25 quarters since. The position peaked at $4.22M in Q2 2013. 400 funds tracked by Wall St. Rank hold ALNY as of Q2 2021.

  • QS Investors held 2,124 shares of Alnylam Pharmaceuticals worth $361K as of Q2 2021.
  • QS Investors sold 200 Alnylam Pharmaceuticals shares in Q2 2021, an estimated $29.3K.
  • Alnylam Pharmaceuticals made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #865 holding.
  • QS Investors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 25 quarters since.
  • QS Investors's Alnylam Pharmaceuticals position peaked at $4.22M in Q2 2013.
  • 400 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.